Research Reports
Veeda Clinical Research Unlisted Shares
Veeda Clinical Research company logo

Veeda Clinical Research Unlisted Shares

DMAT
PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX
High

₹560

Low

₹467

Return

-16.61%

Veeda Clinical Research Essentials

As of March 25, 2026, Veeda Clinical Research, Unlisted Shares are trading at ₹467.00 per share and face value is ₹2.00/share, with a 52-week high of ₹535.00 and 52-week low of ₹467.00. The minimun lot size is 500 shares, and the shares are traded on .
ISIN
info icon
INE01HQ01026
Face Value
info icon
2
Total Shares
info icon
6,57,77,495
Market Cap
info icon
3,071.81 Cr
Profit After Tax
info icon
0 None
Total Revenue
info icon
0 None
Sector
info icon
Health Care
Sub-sector
info icon
Pharmaceuticals
Category
info icon
Pre IPO

About Veeda Clinical Research

  • Overview: Veeda Clinical Research, a leading CRO in India, has been operating for two decades, providing comprehensive services across various stages of drug development including preclinical, early phase, and late-phase clinical trials, bioanalytical assessment, and drug launch.
  • Technical Expertise: The organization specializes in pharmacokinetics (PK) studies and trials for generic molecules, new chemical entities, large molecules, and biosimilars, with an impressive ISR (Incurred Sample Reanalysis) rate of >95%, surpassing the USFDA recommended rate of 67%.
  • Service Spectrum: Veeda offers bioavailability (BA) & bioequivalence (BE) studies, bioanalytical research, medical writing, pharmacovigilance, preclinical trials, clinical trials (Phase I to Phase III), biosimilars, biopharmaceutics, data science, and post-marketing surveillance.
  • Bioanalytical Research: Developed over 1,000 bioanalytical methods, including 860 generics, 70+ complex generics, 30+ large molecule assays, and 70+ in-house methods.
  • Clinical Trial Expertise: Provides a range of clinical development programs to pharmaceutical, biotech, generic, and medical device companies, ensuring fully ICH-GCP compliant operations, including early phase (Phase I) and late phase (Phase II & III) clinical trials.
  • Biosimilars: Through a joint venture with Ingenuity Biosciences, Veeda offers specialized clinical services including PK antidrug antibodies, neutralizing antibodies, and biomarker assays, as well as characterization and comparability testing.
  • Global Reach: With a significant client base in North America, Europe, and Asia, Veeda generates approximately 70% of its revenue from overseas clients.
  • Facilities: Operates around 7 facilities, each catering to different stages of the drug development cycle, and has a subsidiary, Bioneeds, for preclinical research, providing an operational edge.
  • Clients: Veeda Clinical Research has completed studies for numerous high-profile clients worldwide, including Dr. Reddy’s Laboratories Limited, Mankind Pharma Limited, and Granules India Limited in India; Laboratorios Liconsa, S.A (Chemo) in Europe; Novugen Pharma (Malaysia) SDN. BHD. in Malaysia; Sunshine Lake Pharma Co. Ltd and Ǫilu Pharmaceutical Co., Ltd in China; and Upsher-Smith Laboratories LLC and Osmotica Pharmaceutical US LLC in the USA.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Veeda Clinical Research Media

News
Articles
Videos
Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation
Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation
28 Apr 2024
Moneycontrol
Veeda Clinical Research buys European CRO Heads for an undisclosed sum
Veeda Clinical Research buys European CRO Heads for an undisclosed sum
25 Mar 2024
Business Standard
CX Partners Backed Veeda Gets SEBI Nod For IPO
CX Partners Backed Veeda Gets SEBI Nod For IPO
27 Dec 2021
VC Circle

Frequently Asked Question (FAQs)

What is the Veeda Clinical Research Unlisted Share Price?

The Veeda Clinical Research Share Price is Rs 529

Who is the CEO of Veeda clinical research?

The CEO of Veeda Clinical Research is Dr. Mahesh Bhalgat.

Veeda Clinical Research

₹ 467

cartIcon